Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.54 |
| ▸ | GCGR | P47871 | 1/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7090733 | 0.90 | PTGS2 (0.62) | PTGS2PTGS1FAAHKCNH2ALDH1A1 | |
| SCHEMBL7085305 | 0.89 | MAPK13 (0.54) | PTGS2PTGS1MAPK13GCGRMAPK12 | |
| SCHEMBL7087766 | 0.82 | PTGS2 (0.59) | PTGS2PTGS1FAAHKCNH2 | |
| SCHEMBL7089544 | 0.82 | PTGS2 (0.61) | PTGS2PTGS1FAAHKCNH2 | |
| SCHEMBL7084156 | 0.80 | PTGS1 (0.74) | PTGS2PTGS1MAPK13MAPK12MAPK11 | |
| SCHEMBL27814811 | 0.79 | MAPK13 (0.48) | MAPK13GCGRMAPK12MAPK11MAPK14 | |
| SCHEMBL7085202 | 0.78 | CA12 (0.50) | PTGS2PTGS1MAPK13MAPK12MAPK11 | |
| SCHEMBL7090068 | 0.78 | PTGS2 (0.62) | PTGS2PTGS1 | |
| SCHEMBL5597068 | 0.76 | PTGS1 (0.75) | PTGS2PTGS1MAPK13GCGRMAPK12 | |
| SCHEMBL8800641 | 0.76 | PTGS2 (0.54) | PTGS2PTGS1MAPK13GCGRMAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
| EP-0772601-B1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6426360-B1 | ANTIARTHRITIC AGENTS | G D SEARLE & CO. | 2002-07-30 | — | — | US | disclosed |
| EP-1211244-A2 | 4,5-substitued imidazolyl compounds for the treatment of inflammation | G.D. Searle & Co. (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-0772601-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5620999-A | ANTIARTHRITIC, ANALGESIC AND ANTIPYRATIC AGENT | G.D. SEARLE & CO. | 1997-04-15 | — | — | US | disclosed |
| WO-1996003387-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | PTGS2 122/4885PTGS1 114/4885MAPK13 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.